These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20833281)

  • 1. Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases.
    Selvi BR; Cassel JC; Kundu TK; Boutillier AL
    Biochim Biophys Acta; 2010; 1799(10-12):840-53. PubMed ID: 20833281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders.
    Ganai SA; Banday S; Farooq Z; Altaf M
    Pharmacol Ther; 2016 Oct; 166():106-22. PubMed ID: 27411674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools.
    Anne-Laurence B; Caroline R; Irina P; Jean-Philippe L
    Subcell Biochem; 2007; 41():263-93. PubMed ID: 17484132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting specific HATs for neurodegenerative disease treatment: translating basic biology to therapeutic possibilities.
    Pirooznia SK; Elefant F
    Front Cell Neurosci; 2013; 7():30. PubMed ID: 23543406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders.
    Rouaux C; Loeffler JP; Boutillier AL
    Biochem Pharmacol; 2004 Sep; 68(6):1157-64. PubMed ID: 15313413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.
    Saha RN; Pahan K
    Cell Death Differ; 2006 Apr; 13(4):539-50. PubMed ID: 16167067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration.
    Rouaux C; Jokic N; Mbebi C; Boutillier S; Loeffler JP; Boutillier AL
    EMBO J; 2003 Dec; 22(24):6537-49. PubMed ID: 14657026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration.
    Ganai SA; Ramadoss M; Mahadevan V
    Curr Neuropharmacol; 2016; 14(1):55-71. PubMed ID: 26487502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human neuronal cells: epigenetic aspects.
    Kukucka J; Wyllie T; Read J; Mahoney L; Suphioglu C
    Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
    Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
    Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
    Ziemka-Nalecz M; Jaworska J; Sypecka J; Zalewska T
    J Neuropathol Exp Neurol; 2018 Oct; 77(10):855-870. PubMed ID: 30165682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease.
    Hegarty SV; O'Leary E; Solger F; Stanicka J; Sullivan AM; O'Keeffe GW
    Neurotox Res; 2016 Oct; 30(3):510-20. PubMed ID: 27256286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation.
    Vecsey CG; Hawk JD; Lattal KM; Stein JM; Fabian SA; Attner MA; Cabrera SM; McDonough CB; Brindle PK; Abel T; Wood MA
    J Neurosci; 2007 Jun; 27(23):6128-40. PubMed ID: 17553985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
    Konsoula Z; Barile FA
    J Pharmacol Toxicol Methods; 2012; 66(3):215-20. PubMed ID: 22902970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator.
    Chatterjee S; Cassel R; Schneider-Anthony A; Merienne K; Cosquer B; Tzeplaeff L; Halder Sinha S; Kumar M; Chaturbedy P; Eswaramoorthy M; Le Gras S; Keime C; Bousiges O; Dutar P; Petsophonsakul P; Rampon C; Cassel JC; Buée L; Blum D; Kundu TK; Boutillier AL
    EMBO Mol Med; 2018 Nov; 10(11):. PubMed ID: 30275019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylases in memory and cognition.
    Penney J; Tsai LH
    Sci Signal; 2014 Dec; 7(355):re12. PubMed ID: 25492968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for histone deacetylases in the cellular and behavioral mechanisms underlying learning and memory.
    Mahgoub M; Monteggia LM
    Learn Mem; 2014 Oct; 21(10):564-8. PubMed ID: 25227251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HAT and HDAC: Enzyme with Contradictory Action in Neurodegenerative Diseases.
    Singh R; Rathore AS; Dilnashin H; Keshri PK; Gupta NK; Prakash SAS; Zahra W; Singh S; Singh SP
    Mol Neurobiol; 2024 Nov; 61(11):9110-9124. PubMed ID: 38587698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
    Gray SG; Dangond F
    Epigenetics; 2006; 1(2):67-75. PubMed ID: 17998807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise.
    Mai A; Rotili D; Valente S; Kazantsev AG
    Curr Pharm Des; 2009; 15(34):3940-57. PubMed ID: 19751207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.